Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial summarizes recent research on novel cardiovascular risk markers and strategies, emphasizing the importance of targeted interventions and early detection to reduce the global cardiovascular burden.
This edition of the European Journal of Preventive Cardiology focuses on various topics related to cardiovascular risk markers that can be targeted for enhanced cardiovascular prevention. Atrial fibrillation (AF) increases the risks of various vascular diseases including stroke and heart failure (HF),1 and its contribution to cardiovascular (CV) morbidity and mortality is expected to increase over the years along with the aging of populations.2 The identification of clinically useful risk factors and biomarkers for AF prevention strategies could play an important role. Maezono et al.3 conducted a prospective study including 2829 community-dwelling Japanese aged ≥40 years without prior AF. After a 10-year follow-up, they demonstrated a significant association between higher day-to-day blood pressure variability (BPV) assessed by home blood pressure monitoring and risk for the development of AF. Day-to-day home BPV was defined as coefficient of variation (CoV) of home systolic blood pressure for 28 days, and patients in the highest quartile of CoV had a 2.20-fold [95% confidence intervals (CIs): 1.18–4.08] increased risk of developing AF compared with those in the lowest quartile. Surprisingly, the association between BPV and the development of AF tended to be stronger in participants without hypertension which is a known risk factor for AF. The assessment of BPV, together with already known risk factors, could lead to a better surveillance of patients considered to be at higher risk of developing AF allowing an early treatment of the arrhythmia. Despite a reduction in cardiovascular disease (CVD) mortality worldwide,4,5 ischaemic heart diseases (IHDs) and stroke were responsible for ∼27% of the global mortality in 2019.6 Strategies for the prevention of CVDs are important to minimize the CVD burden. Smoking is a strong independent risk factor for CV events: smokers have a two-fold increase in the risk of CV mortality compared with never smokers.7 The implementation of tobacco control measures led to a significant reduction in the prevalence of smoking between 1990 and 2019. While the global trends in smoking-attributed mortality from individual components of CVD, such as IHD, have been described, data are lacking on the trends in overall CVD mortality attributed to smoking. Minhas et al.8 have analysed the trends and distribution of smoking-attributed CVD both globally and in different geographic regions and countries using the Global Burden of Disease Study 2019. The burden of CVD attributed to smoking has declined worldwide between 1990 and 2019 but not homogenously between different countries and regions: Eastern Europe had the highest death rate and Andean Latin America had the lowest death rate in 2019. Also, countries with high socio-economic status had lower death rates from smoking-attributed CVD. This highlights the need for targeted interventions to reduce the burden of smoking-attributed CVD. The main treatment of aortic aneurysms (AAs) is interventional (endovascular or surgery) to avoid fatal complications; however, early repair does not reduce mortality for patients with small AA measuring 40–54 mm.9 Identifying drug targets that can act on AA is crucial since no medications specifically target this disease. There are conflicting data derived from observational studies regarding the role of lipid-lowering drug in reducing the progression of AA dilation being susceptible to confounding and reverse causation, making it challenging to generate causal evidence. Gao et al.10 conducted a drug–target Mendelian randomization to overcome some of these limitations. They demonstrated that the risk of AAs was positively correlated with high expression of HMGCR, PCSK9, and CETP highlighting that the corresponding lipid-lowering drugs may be preferred for preventing arterial aneurysms in high-risk individuals with dyslipidaemia. The pathophysiologic mechanisms underlying AF are complex, and cardiometabolic disorders including obesity, hypertension, diabetes mellitus (DM), coronary heart disease, HF, and stroke are intertwined with AF. Studies addressing isolated management of a specific disorder have yielded inconsistent results for preventing AF.11 Investigating multi-morbidity rather than focusing solely on single diseases provides a more accurate representation of the health challenges individuals face. Lu et al.12 investigated the association between the burden of cardiometabolic disorders with new-onset AF and lifetime risk of AF incidence among 4101 men and 5421 women from the Rotterdam Study cohort. They observed a stronger association between a larger burden of cardiometabolic disorders and incident AF among women [hazard ratio (HR): 1.33% and 95% CI: 1.22–1.46], compared with men [1.18 (1.08–1.29); P for sex interaction < 0.05]. Among participants aged 55 years or older, the lifetime risk of AF was higher in healthy men (25.2%) compared with healthy women (16.3%). Identifying the association between cardiometabolic multi-morbidity and incident AF would aid in proper risk stratification, early detection, and targeted interventions aimed at mitigating the development of AF in high-risk populations with comorbid cardiometabolic conditions. There is a growing awareness that microcirculatory functional deterioration is associated with CVD.13 However, there is a lack of larger cross-sectional and longitudinal studies.13 Local forearm skin peak haemoglobin oxygen saturation after induced ischaemia during a prolonged brachial occlusion (OxyP) can be used as a marker of microvascular function with good reproducibility.14 Bergstrand et al.15 conducted a study of 3809 individuals 50–65 years old without CVD or DM from the SCAPIS study. They observed a relative risk increase of 53% for individuals with OxyP values in the lowest quartile (Q1; impaired microvascular function) compared with those with the highest values of OxyP (Q4) with a mean SCORE2 of 5.8 and 3.8%, respectively. The higher CV risk remained even when adjusting for body mass index and high-sensitivity C-reactive protein. OxyP may serve as a microcirculatory functional marker of subclinical atherosclerosis and CVD risk that is not detected by structural assessments. Cardiovascular diseases are the leading cause of death in Western countries.16 In clinical practice, as recommended by European guidelines,17 significant attention is given to the lipid profile, particularly focusing on non-HDL cholesterol levels. Emerging data highlight the importance of apolipoproteins in CV health. Zhang et al.18 have demonstrated the utility of the ApoB/ApoA1 ratio, emphasizing the negative prognostic effect of apolipoprotein B and the potential positive prognostic effect of apolipoprotein A1 on CV health. Further research could enhance our understanding in this area and lead to the potential integration of apolipoprotein management in clinical practice. Coronary artery calcium (CAC) is a known indicator of atherosclerosis and a significant CV risk factor for cardiac events.19 Coronary artery calcium evaluation, which requires a computed tomography (CT) scan without contrast agent and uses a low-dose radiation, has garnered attention as a potential risk stratifier in various clinical scenarios. Wen et al.20 conducted a study demonstrating that aortic valve calcification can be evaluated alongside CAC. They found that both conditions independently and synergistically predict the risk of CV events and all-cause mortality. Computed tomography with low-dose radiation and no contrast agent injection can accurately identify CAC, an established CV risk factor.17 A meta-analysis by Haq et al.21 confirmed the prognostic role of CAC evaluation in individuals under 55 years of age. They found that a CAC score higher than 100 is a significant risk factor for both CVD and mortality. Therefore, when patients undergo chest CT for various reasons, CAC should always be evaluated. Those with higher CAC scores should receive a more intensive evaluation to reduce the risk of future cardiac events. Many efforts in clinical practice focus on reducing CVD through strategies such as lowering LDL cholesterol, achieving weight loss, and managing arterial pressure. However, when physicians advise patients to modify their lifestyle to reduce CV risk, adequate time is not always spent on proper counselling, leading patients to potentially underestimate their risk. Research by Whitmore et al.22 has demonstrated that active patient participation by providing the visualization of atherosclerotic vascular plaque can significantly improve understanding of CV risk and lead to better management of risk factors. Their findings suggest that engaging patients in their own care process is crucial for effective treatment and risk reduction. Significant efforts have been dedicated to evaluating CV risk factors to tailor prevention and treatment strategies, thereby reducing the overall burden of CVD in the general population.23 Age is a well-known CV risk factor.24 Clonal haematopoiesis of indeterminate potential (CHIP), characterized by the clonal expansion of haematopoietic cells with age-related recurrent somatic mutations in the absence of other haematologic abnormalities, has been associated with aging and may serve as a stratifier risk factor.25 Lee et al.26 demonstrated that CHIP carriers with high levels of LDL cholesterol are associated with early atherosclerosis. Therefore, further studies are needed to better understand the prognostic role of CHIP carriers and how this information should be utilized. A deeper understanding of the pathophysiology could lead to future CV risk prevention treatments and help reduce the CV risk burden. Temperature and weather conditions can significantly impact health, particularly concerning CV and respiratory diseases.27 Achebak et al.28 have demonstrated that both high and low ambient temperatures increase the risk of death, especially from respiratory and CV conditions. Given the ongoing changes in weather and temperature patterns, it is crucial to pay attention to reducing exposure to extreme temperatures to mitigate their negative effects on all-cause mortality in the general population. Arterial hypertension is often underdiagnosed and undertreated, despite being a well-known CV risk factor, primarily because it can occur without symptoms.29 Normotensive individuals with no previous CVD may not regularly monitor their blood pressure at home. Carlén et al.30 have demonstrated that the blood pressure response to an exercise test during cycle ergometry in normotensive individuals can be a useful tool for identifying those at higher risk of developing arterial hypertension. Traditionally, exercise testing is used as a risk stratifier for atherosclerotic diseases, but it can also effectively identify individuals at higher risk of arterial hypertension. Identifying these individuals allows for more intensive cardiological evaluation and early treatment of CV risk factors, improving overall CV health.
No takes yet. Share an insight, caveat, or question.
Disabato et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: